Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older who have been diagnosed with advanced HPV-positive cervical cancer (stage IB1 to IVA) and have completed their primary treatment (such as surgery, radiation, and/or platinum-based chemotherapy) within the last 12 months.
• People currently receiving a specific type of immune therapy (anti-PD-1 or anti-PD-L1) after chemoradiation, as recommended by their doctor, as this treatment may continue alongside the study drug.
• People with no signs of remaining or returning cancer, confirmed by imaging and clinical checks within 8 weeks before joining.
• People who do not have HIV infection.
• People who test negative for Hepatitis B.
• People who test negative for Hepatitis C.
• People who are willing and able to follow all study procedures and sign a consent form.
• People whose blood test results show that their organs (including bone marrow, liver, and kidneys) are functioning at an adequate level as defined by the trial (confirm specific values with trial site).
• People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are fully active or have only minor limitations in physical activity.
• People whose side effects from previous treatment have largely resolved to a mild level or lower before joining the trial.
• People who are willing and able to care for the vaccination site for one month after receiving the vaccine, and to avoid close contact during that time with: children under 1 year old, pregnant women, and people at high risk of serious reactions to the vaccinia virus (such as those with eczema or immune system conditions).

Who may not be able to join:

• Women who still have the ability to become pregnant (for example, those who had fertility-preserving surgery), unless they agree to either remain sexually abstinent, have a partner who has had a vasectomy, or consistently use an approved contraception method throughout the first 6 months of the study.
• Women who are currently breastfeeding, as breastfeeding would need to stop if enrolled in the study.
• People who have been diagnosed with an immune system deficiency condition, whether acquired, inherited, or present from birth.
• People who need ongoing treatment with immune-suppressing medications (such as cyclosporine, steroids, or certain other drugs), either long-term or within 30 days before the first vaccination.
• People who have received any blood product within 30 days before signing the consent form.
• People who need ongoing blood-thinning (anticoagulation) treatment during the study period.
• People who have previously had a severe allergic reaction to a vaccine or any of its ingredients.
• People who have participated in another clinical trial involving an investigational drug or device within 30 days of signing the consent form.
• People with a known active condition affecting the brain or spinal cord.
• People who have had surgery within 30 days before the first vaccination, not including minor procedures.
• People with an uncontrolled ongoing illness, active infection, or mental health or personal circumstances that would make it difficult to follow the study requirements.
• People with an active autoimmune disease such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn's disease, multiple sclerosis, or ankylosing spondylitis.
• People with a history of inflammation of the heart muscle (myocarditis) or the lining around the heart (pericarditis).
• People with a known underlying heart condition, such as heart failure, uncontrolled irregular heartbeat, unstable chest pain, or a heart attack or stroke within the past 6 months.
• People who have active, non-healed wounds or certain active skin conditions — or whose close household or social contacts have these — including eczema, burns, impetigo, chickenpox, cold sores, severe acne, severe nappy rash with broken skin, psoriasis, lichen planus, or Darier disease.
• People with a history or current diagnosis of atopic dermatitis.
• People who are unwilling or unable to follow vaccination site care instructions for one month after receiving the vaccine, or who cannot avoid close contact with children under 1 year old, pregnant women, or people at high risk of serious reactions to the vaccinia virus.

Important: Always verify eligibility with the trial site directly before applying.